Article
Thesan Pharmaceuticals has been given $16 million in series A funding to develop novel treatments for inflammatory skin disorders.
Top 5 Articles of the Week: February 9-14
The Cutaneous Connection: Intervening in AD Progression for Pediatric Patients
The Rx Recap: February 9-15
The Cutaneous Connection: Navigating Systemic Therapies in Atopic Dermatitis
Bridging Dermatology and Psychological Support
Nektar's Jonathan Zalevsky, PhD, Dives Into Rezpegaldesleukin Fast Track Designation for Atopic Dermatitis